Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib

MLA

Jindrich Finek, et al. “Serum Albumin Is a Strong Predictor of Survival in Patients with Advanced-Stage Non-Small Cell Lung Cancer Treated with Erlotinib.” Neoplasma, vol. 63, no. 3, Mar. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2c8fa4684e6b385172f0ac4e2d22bb8b&authtype=sso&custid=ns315887.

APA

Jindrich Finek, Marek Minarik, Jaroslav Racek, Radek Kucera, Ondrej Sorejs, Zbyněk Bortlíček, L Benesova, Ondřej Fiala, Miloš Pešek, & Ondřej Topolčan. (2016). Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib. Neoplasma, 63(3).

Chicago

Jindrich Finek, Marek Minarik, Jaroslav Racek, Radek Kucera, Ondrej Sorejs, Zbyněk Bortlíček, L Benesova, Ondřej Fiala, Miloš Pešek, and Ondřej Topolčan. 2016. “Serum Albumin Is a Strong Predictor of Survival in Patients with Advanced-Stage Non-Small Cell Lung Cancer Treated with Erlotinib.” Neoplasma 63 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2c8fa4684e6b385172f0ac4e2d22bb8b&authtype=sso&custid=ns315887.